Interventions for antipsychotic‐induced amenorrhoea
References
Additional references
Adams CE, Awad GA, Rathbone J, Thornley B, Soares‐Weiser K. Chlorpromazine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD000284.pub3; PUBMED: 24395698]
Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
Bargiota SI, Bonotis KS, Messinis IE, Angelopoulos NV. The effects of antipsychotics on prolactin levels and women’s menstruation. Schizophrenia Research and Treatment 2013;2013:10. [DOI: 10.1155/2013/502697]
Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'etude des indices d'efficacite]. Therapie 1999;54(4):405‐11. [PUBMED: 10667106]
Bushe C, Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. Journal of Psychopharmacology 2007;21(7):768‐73.
Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E. Cabergoline treatment of risperidone‐induced hyperprolactinemia: a pilot study. Journal of Clinical Psychiatry 2004;65(2):187‐90.
Klein DA, Poth MA. Amenorrhea: an approach to diagnosis and management. American Family Physician 2013;87(11):781‐8.
Deeks J. Issues in the selection for meta‐analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25‐28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Divac N, Prostran M, Jakovcevski I, Cerovac N. Second‐generation antipsychotics and extrapyramidal adverse effects. BioMed Research International 2014;2014:6 pages.
Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623‐9.
Donner A, Klar N. Issues in the meta‐analysis of cluster randomized trials. Statistics in Medicine 2002;21(19):2971‐80.
Duncan D. Treatment of psychotropics induced hyperprolactinaemia. Psychiatry Bulletin 1995;19:755‐7.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315(7109):629‐34.
Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta‐analyses involving cross‐over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140‐9.
Finny P, Tharyan P, Thomas N. Role of jasmine flower extract in management of antipsychotic medication induced amenorrhoea. International Endocrinology Conference, 2005, Qatar. 2005.
Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta‐analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(1):7‐10.
Gulliford MC. Components of variance and intraclass correlations for the design of community‐based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149(9):876‐83.
Haddad PM, Wieck A. Antipsychotic‐induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004;64(20):2291‐314. [PUBMED: 15456328]
Hammer MB, Arana GW. Hyperprolactinaemia in antipsychotic treated patients: guidelines for avoidance and management. CNS Drugs 1998;10:209‐22.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60.
Higgins JPT, Green S (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi‐Health Systems, 1986.
Keller R, Mongini F. Switch to quetiapine in antipsychotic agent‐related hyperprolactinemia. Neurological Sciences 2002;23(5):233‐5. [PUBMED: 12522680]
Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003;28 Suppl 2:55‐68. [PUBMED: 12650681]
La Torre D, Faloni A. Pharmacological causes of hyperprolactinemia. Journal of Therapeutics and Clinical Risk Management 2007;3(5):929‐51.
Lee MS, Song HC, An H, Yang J, Ko YH, Jung IK, et al. Effect of bromocriptine on antipsychotic drug‐induced hyperprolactinemia: eight‐week randomized, single‐blind, placebo‐controlled, multicenter study. Psychiatry and Clinical Neurosciences 2010;64(1):19‐27. [PUBMED: 19968833]
Leon AC, Mallinckrodt CH, Chuang‐Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001‐5. [PUBMED: 16905632]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366‐71. [PUBMED: 16199797]
Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2‐3):231‐8. [PUBMED: 15982856]
Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatment analysis. Lancet 2013;382(9896):951‐62.
Madhusoodanan S, Parida S, Jimenez C. Hyperprolactinemia associated with psychotropics ‐ a review. Human Psychopharmacology 2010;25(4):281‐97.
Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249‐52.
Messias E, Chen CY, Eaton WW. Epidemiology of schizophrenia: review of findings and myths. Psychiatric Clinics of North America 2007;30(3):323‐38.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799‐812.
Paul T, Ravan JR, Thomas N, Thomas N, Samuel P, Braganza D. Risperidone associated changes in prolactin and bone mineral density: a study from South India. Endocrine Abstracts 2013;31:17.
Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs March 2014;28(5):421‐53.
Rummel‐Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Asenjo‐Lobos C, et al. Head‐to‐head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta‐analysis. Schizophrenia Research 2010;123(2‐3):225‐33.
Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophrenia Bulletin 2009;35(5):937‐48.
Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic‐induced hyperprolactinemia: a placebo‐controlled trial. American Journal of Psychiatry 2007;164(9):1404‐9.
Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic‐induced hyperprolactinemia on the hypothalamic pituitary gonadal axis. Journal of Clinical Psychopharmacology 2002;22:109‐14.
Staller J. The effect of long term antipsychotic on prolactin. Journal of Child and Adolescent Psychopharmacology 2006;16:317‐26.
Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.handbook.cochrane.org.
Turkington RW. Human prolactin: an ancient molecule provides new insights for clinical medicine. American Journal of Medicine 1972;53(4):389‐94.
Turner T. Chlorpromazine: unlocking psychosis. BMJ (Clinical research ed.) 2007;334(Suppl 1):s7. [PUBMED: 17204765]
Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PG. Methods for evaluating area‐wide and organisation‐based interventions in health and health care: a systematic review. Health Technology Assessment 1999;3(5):iii‐92.
Wieck A, Haddad PM. Antipsychotic‐induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. British Journal of Psychiatry 2003;182:199‐204. [PUBMED: 12611781]
Wistedt B, Wiles D, Kolakowska T. Slow decline of plasma drug and prolactin levels after discontinuation of chronic treatment with depot neuroleptics. Lancet 1981;1(8230):1163. [PUBMED: PMID: 6112518]
Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El‐Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254‐7.
Yuan HN, Wang CY, Sze CW, Tong Y, Tan QR, Feng XJ, et al. A randomized, crossover comparison of herbal medicine and bromocriptine against risperidone‐induced hyperprolactinemia in patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(3):264‐370.
